Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05231 (
interleukin-6
)
23,907
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Oncostatin M
(
OSM
), which is predominantly expressed in bone marrow, is a member of the
interleukin-6
family of cytokines, and appears to play important roles in hematopoiesis and the development of the liver. Recently, specific beta subunit of
OSM
receptor (OSMRbeta) was isolated from LO cells originated from aorta-gonad-mesonephros (AGM) region. In this study, we performed in situ hybridization to explore the expression pattern of OSMRbeta during murine embryogenesis, postnatal development, and in adult tissues. At 11.5 days postcoitum (dpc), the expression of OSMRbeta was first detected in aortic endothelial cells of the AGM region. At 14.5dpc, its gene expression was clearly observed in the primordia of some organs, including liver, thymus, choroid plexus, and limb, and persisted into postnatal mice. After birth, its gene expression became detectable in the other organs, such as lymph node, bone, heart, kidney, small intestine, nasal cavity, and lung.
...
PMID:Developmental expression pattern of oncostatin M receptor beta in mice. 1204 76
The expression of oncostatin M and leukemia inhibitory factor (LIF), JAK-STAT activators and members of the
interleukin-6
family of cytokines, were examined in a series of primary ovarian carcinomas using immunohistochemistry. The malignant epithelial cells of all 29 ovarian carcinomas examined expressed oncostatin M; none expressed LIF.
Oncostatin M
can activate two related receptors, one consisting of a low-affinity LIF receptor subunit, LIFR beta, which forms a heterocomplex with the gp130 signal transducing protein and can recognize both oncostatin M and LIF, and a second heterocomplex consisting of a subunit that specifically recognizes oncostatin M, OSMR beta, and the gp130 protein. By immunohistochemistry, 25 of 25 ovarian carcinomas examined expressed the LIFR beta subunit in the malignant epithelial cells (all samples express gp130), and two-thirds the ovarian carcinomas studied expressed OSMR beta mRNA as determined by RT-PCR. Thus oncostatin M and its receptors are commonly coexpressed in malignant ovarian epithelial cells, and represent a potential autocrine loop in this tumor type. STAT3, of one the signaling proteins downstream of the oncostatin M/LIF receptors, was found in its phosphorylated, activated form (phosphotyrosine 705 STAT3) in the malignant epithelial cells of 17 of 23 ovarian carcinomas examined (74%) as determined by immunohistochemistry; this suggests that this protein is constitutively activated in most ovarian carcinomas, as it is in many other human malignancies. Recombinant human
Oncostatin M
(rhOSM) can induce the transient tyrosine 705 phosphorylation of STAT3 in serum-starved LIFR beta/OSMR beta expressing ovarian carcinoma cell lines, but does not alter cell growth and effects only a modest increase in the apoptotic rate in these cultured cells.
Oncostatin M
and its receptors may be part of a network of cytokine systems within ovarian carcinomas that may act to maintain STAT3 in its activated form, a phenomenon associated with the malignant phenotype.
...
PMID:Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas. 1206 40
1.
Oncostatin M
(
OSM
), a member of the
interleukin-6
(
IL-6
) cytokine family, acts on a variety of cells and elicits diversified biological responses, suggesting potential roles in the regulation of cell survival, differentiation and proliferation. 2. We have examined the effect of
OSM
on the regulation of human lung fibroblast proliferation, collagen production and spontaneous apoptosis. The proliferative effects of
OSM
(0.5 - 100 ng ml(-1)) were assessed using a MTS assay as well as [(3)H]-thymidine incorporation and cell counts at 24 and 48 h. Hydroxyproline was measured as an index of procollagen production by high pressure liquid chromotography (HPLC). Apoptosis was determined by annexin staining. 3.
OSM
enhanced the mitotic activity of lung fibroblasts in a time and dose dependent manner. Maximum proliferation of 57% above control was observed after incubation for 48 h with 2 ng ml(-1)
OSM
(P<0.05). 4. Incubation with the mitogen activated protein kinase (MAPK) kinase inhibitor, PD98059 or the tyrosine kinase inhibitor, genestein both significantly reduced the mitogenic effect of
OSM
(P<0.05). 5. In contrast, proliferation in response to
OSM
was not regulated by induction of cyclo-oxygenase and subsequent prostaglandin E(2) (PGE(2)) release or by
IL-6
. 6.
OSM
also stimulated fibroblasts to synthesize pro-collagen by a maximum of 35% above control levels after 48 h (P<0.05). 7.
OSM
significantly inhibited the spontaneous apoptosis of fibroblasts at 24 and 48 h. 8. These results provide evidence that
OSM
has pro-fibrotic properties and suggest that it may play a role in normal lung wound repair and fibrosis.
...
PMID:Oncostatin M stimulates proliferation, induces collagen production and inhibits apoptosis of human lung fibroblasts. 1208 89
Oncostatin M
(
OSM
) is a glycoprotein cytokine that is produced by activated T-lymphocytes, monocytes, and macrophages. In a DNA synthesis assay,
OSM
reduced tritiated thymidine incorporation by 53% in Calu-1 lung carcinoma cells. Radiolabeled cDNAs from untreated Calu-1 cells and 30-h
OSM
-treated cells were used to probe duplicate nylon membrane cDNA expression arrays. This study revealed
OSM
-mediated expression of mRNAs encoding tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1). Northern blot analysis showed that the steady-state level of tPA mRNA is nearly undetectable in Calu-1 cells. Exposure of these cells to
OSM
for 30 h increased tPA mRNA expression by 20-fold and PAI-1 mRNA expression by 5-fold. Exposure of these cells to other gp130 receptor family cytokines, including leukemia inhibitory factor (LIF),
interleukin-6
(
IL-6
), and IL-11, do not significantly affect DNA synthesis or induction of tPA/PAI-1. Western blot studies demonstrated that
OSM
mediates a marked increase in secretion of the tPA protein. Secreted tPA was present in the conditioned medium almost exclusively as tPA/PAI-1 complexes. Inhibitor studies demonstrated that
OSM
-mediated induction of tPA and PAI-1 mRNAs is largely dependent upon activation of the MEK1/2 pathway. The JAK3/STAT3 pathway potentially serves a secondary role in these regulatory events.
...
PMID:Oncostatin M induces tissue-type plasminogen activator and plasminogen activator inhibitor-1 in Calu-1 lung carcinoma cells. 1209 Jul 57
Oncostatin M
(
OSM
) is a cytokine of the
interleukin-6
(
IL-6
) family secreted by activated monocytes, and is expressed in atherosclerotic plaque. Smooth muscle cells (SMC), by expressing tissue factor (TF) and tissue factor pathway inhibitor (TFPI) can contribute to the thrombogenicity of atherosclerotic plaque. Consequently, the aim of this study was to evaluate the effects of
OSM
on the procoagulant activity of SMC. We observed that
OSM
induced in a concentration-dependent manner a potent procoagulant activity (PCA) that was related in part to an increased synthesis of TF, both at the cell membrane and in SMC lysates. The increased expression of TF on SMC membrane induced by
OSM
was sustained and was still observed 24 h after stimulation by
OSM
.
IL-6
and leukaemia inhibitory factor (LIF), two
OSM
-related cytokines, did not significantly modify TF expression at the surface of SMC. In addition to its effects on TF,
OSM
decreased the secretion of TFPI in the supernatants of SMC, as well as in the lysates, but was devoid of effect on TFPI bound at the membrane of SMC.
IL-6
and LIF reduced also TFPI secretion, which could explain why the PCA of SMC lysates treated by
IL-6
or LIF was increased, despite an absence of effect on TF expression. In conclusion, these data support the hypothesis that by increasing the PCA of SMC,
OSM
might be involved in the thrombotic complications associated with plaque rupture.
...
PMID:Oncostatin M induces procoagulant activity in human vascular smooth muscle cells by modulating the balance between tissue factor and tissue factor pathway inhibitor. 1213 73
Cdk9 is a member of the Cdc2-like family of kinases. It binds to members of the family of cyclin T (T1, T2a and T2b) and to cyclin K. The Cdk9/cyclin T complex appears to be involved in regulating several physiological processes. In fact Cdk9 is the kinase of the P-TEFb complex, involved in basal transcription. Cdk9 has also been described as the kinase of the TAK complex, homologous to P-TEFb and involved in HIV replication. Here we show that Cdk9 interacts with gp130, the receptor of the
Interleukin-6
(
IL-6
) family of cytokines, which includes Leukemia Inhibitory Factor (LIF),
Oncostatin M
(
OSM
), Ciliary Neurotrophic Factor (CNTF), Interleukin-11 (IL-11) and Cardiotrophin (CT-1).
IL-6
is a key regulator of hematopoiesis, immunological responses and inflammation. In addition,
IL-6
plays a major role in the endocrine and nervous systems. Signal transduction by gp130 is mediated by physical interaction of the cytoplasmic region of gp130 with cellular kinases and results in the transcriptional activation of cellular and viral genes. We found that Cdk9 interacts in vitro with the cytoplasmic region of gp130 and we succeded in reproducing this interaction in vivo. Cdk9 expression was found both in the nucleus and in the cytoplasm. The binding occurring between Cdk9 and gp130 increased upon
IL-6
stimulation. We also observed that Cdk9 synergized with
IL-6
in inducing the activation of an
IL-6
-responsive reporter plasmid. In summary, these results point to a previously undisclosed role for Cdk9 in signal transduction.
...
PMID:Cdk9, a member of the cdc2-like family of kinases, binds to gp130, the receptor of the IL-6 family of cytokines. 1238 8
Oncostatin M
(
OSM
), a cytokine of the
interleukin-6
family, is expressed in rheumatoid arthritis, multiple sclerosis, multiple myeloma, and other inflammatory and neoplastic conditions. Prostaglandin E(2) (PGE(2)), an eicosanoid also associated with inflammation and cancer, has recently been shown to induce
OSM
expression. We report here that
OSM
in turn induces PGE(2) production by astrocytes and astroglioma cells. More importantly, in combination with the inflammatory mediators IL-1beta, tumor necrosis factor-alpha, and lipopolysaccharide,
OSM
exhibits a striking synergy, resulting in up to 50-fold higher PGE(2) production by astrocytes, astroglioma, and neuroblastoma cell lines. Enhanced PGE(2) production by
OSM
and IL-1beta treatment is explained by their effect on cyclooxygenase-2 (COX-2), an enzyme that catalyzes the committed step in PGE(2) synthesis. Of the enzymes involved in PGE(2) biosynthesis, only COX-2 mRNA and protein levels are synergistically amplified by
OSM
and IL-1beta. Nuclear run-on assays demonstrate that
OSM
and IL-1beta synergistically upregulate transcription of the COX-2 gene, and the mRNA stability assay indicates that COX-2 mRNA is posttranscriptionally stabilized by
OSM
and IL-1beta. To effect synergy on the PGE(2) level,
OSM
signals in part through its gp130/OSMRbeta receptor, since neutralizing antibodies against gp130 and OSMRbeta, but not LIFRbeta, decrease PGE(2) production in response to
OSM
plus IL-1beta. SB202190 and U0126, inhibitors of p38 MAPK and ERK1/2 activation, respectively, inhibit IL-1beta and
OSM
upregulation of COX-2 and PGE(2), indicating that these MAPK cascades are utilized by both stimuli. This mechanism of PGE(2) amplification may be active in brain pathologies where both
OSM
and IL-1beta are present, such as glioblastomas and multiple sclerosis.
...
PMID:Oncostatin M enhances the expression of prostaglandin E2 and cyclooxygenase-2 in astrocytes: synergy with interleukin-1beta, tumor necrosis factor-alpha, and bacterial lipopolysaccharide. 1273 Sep 64
Oncostatin M
belongs to the
interleukin-6
family of cytokines and acts as a multifunctional cytokine during murine embryogenesis and in inflammatory reactions. Although it has been demonstrated that oncostatin M has biological activities on many types of cells, including hepatocytes, dermal fibroblasts and endothelial cells, the roles of oncostatin M in the murine peripheral nervous system remain unclear. Here, we investigated the expression of specific beta-subunit of oncostatin M receptor in the dorsal root ganglia of adult mice. In the adult dorsal root ganglia, beta-subunit of oncostatin M receptor was exclusively expressed in small-sized neurons. Approximately 13% of total dorsal root ganglia neurons in mice contained beta-subunit of oncostatin M receptor. The double-immunofluorescence method revealed that approximately 28% of beta-subunit of oncostatin M receptor-positive neurons contained TrkA immunoreactivity, 63% expressed Ret immunoreactivity and 58% bound isolectin B4. No neuropeptides, including substance P and calcitonin gene-related peptide, were contained in the neurons. In addition, all beta-subunit of oncostatin M receptor-positive neurons expressed both vanilloid receptor 1 and P2X3 purinergic receptor. These neurons projected to the inner portion of lamina II in the dorsal horn of spinal cord and the dermis of skin. Seven days after sciatic nerve axotomy, the expression of beta-subunit of oncostatin M receptor was down-regulated in the lumbar dorsal root ganglia of the injured side. Our study demonstrated that beta-subunit of oncostatin M receptor was expressed in both cell bodies and processes of nonpeptidergic nociceptive neurons in adult mice, suggesting that oncostatin M may affect the nociceptive function of the neurons through the modulation of vanilloid receptor 1 and P2X3 expression.
...
PMID:Expression of oncostatin M receptor beta in a specific subset of nociceptive sensory neurons. 1281 62
Oncostatin M
(
OSM
) is a member of the
interleukin-6
cytokine family, which is involved in definitive hematopoiesis, the development of liver, and local inflammation. However, little is known about the role of
OSM
in the murine CNS. Using Northern blot analysis, we examined the regional distribution of
OSM
receptor beta (OSMRbeta) mRNA in the adult CNS. OSMRbeta mRNA was observed predominantly in the olfactory bulb, and with low levels in the other regions. In situ hybridization shows that OSMRbeta gene expression was found in astrocytes of olfactory bulb, epithelial cells of choroid plexus, and meningeal cells in pia mater. In addition, we investigated the gene expression of OSMRbeta in the developing CNS at different time points. Its gene expression was first observed in large neurons of the hypoglossal nucleus at 14.5 days postcoitum, which was sustained until neonatal mice. OSMRbeta mRNA and protein were mainly localized in the ventral subnucleus of the developing hypoglossal nucleus. Our results suggest that
OSM
contributes to the development of specific subpopulations of both neurons and astrocytes in the murine CNS.
...
PMID:Localization of oncostatin M receptor beta in adult and developing CNS. 1283 58
Oncostatin M
(
OSM
) is a member of the
interleukin-6
family of cytokines, and we have reported previously that the murine
OSM
receptor beta subunit (OSMR) was expressed in some neurons in the adult trigeminal and dorsal root ganglia (DRGs) and in the perineonatal hypoglossal nucleus. In the present study, we investigated the development of OSMR-positive neurons of DRGs in
OSM
-deficient mice. In situ hybridization revealed that OSMR-positive neurons in DRGs began to appear at postnatal day 0 (P0) and reached the adult level at P14. In the DRGs of the
OSM
-deficient mice, vanilloid receptor 1 (VR1)- and P2X3-positive small-sized neurons were significantly decreased. In addition, OSMR-positive neurons decreased, resulting in the reduced number of VR1/P2X3/OSMR-triple positive neurons.
OSM
-deficient mice displayed significantly reduced noxious responses in models of acute thermal, mechanical, chemical, and visceral pain. Thus,
OSM
plays an essential role in the development of a subtype of nociceptive neurons in the DRGs.
...
PMID:Essential function of oncostatin m in nociceptive neurons of dorsal root ganglia. 1498 35
<< Previous
1
2
3
4
5
6
7
8
Next >>